Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2008-06-03
2010-06-29
Davis, Brian J (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C514S653000, C423S647700
Reexamination Certificate
active
07745665
ABSTRACT:
Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
REFERENCES:
patent: 2002/0013372 (2002-01-01), Ekins
patent: 2008/0033011 (2008-02-01), Tung
patent: 9526325 (1995-10-01), None
patent: 0247676 (2002-06-01), None
patent: 02083144 (2002-10-01), None
patent: 2008103924 (2008-08-01), None
patent: 2008151179 (2008-12-01), None
patent: 2008151179 (2008-12-01), None
Drug Report for Phenylephrine (topical, stress urinary incontinence, Plethora), Thomson Investigational Drug Database (Sep. 17, 2008).
Drug Report for Phenylephrine hydrochloride gel (fecal incontinence), SLA Pharma/Ventrus Biosciences, Thomson Investigational Drug Database (Sep. 17, 2008).
Raffel, D.; Sensitivity of [11C] Phenyl-ephrine Kinetics to Mono-amine Oxidase Activity in Normal Human Heart; Journal of Nuclear Medicine (1999), 40(2), 232-238.
Raffel, D.; Influence of Vesicular Storage and Monoamine Oxidase Activity on [11C]Phenylephrine Kinetics: Studies in Isolated Rat Heart; Journal of Nuclear Medicine (1999), 40(2), 323-330.
Couch et al.; The Synthesis of Deuterated Hydroxyphenethylethanolamines and Their Metabolites; Journal of Labelled Compounds and Radiopharma-ceuticals (1983), 20(8), 933-49.
Teng et al.; Synthesis of Tritium Labeled Phenylephrine; Journal of Labelled Compounds and Radiopharma-ceuticals (1978), 15 (Suppl. vol.), 321-4.
Ibrahim et al.; The Mammalian Metabolism of R-(-)-m-Synephrine; Journal of Pharmacy and Pharmacology (1983), 35 (3), 144-7.
Midgley et al.; m-Synephrine: Normal Occurrence in Adrenal Gland; Journal of Neuro- chemistry (1980), 34(5), 1225-30.
del Rosario et al.; Synthesis of [11C](-)-α,α-Dideutero-Phenylephrine For In Vivo Kinetic Isotope Studies; Journal of Labelled Compounds & Radiopharmaceuticals (1995) 36(7), 625-30.
Van Dort et al.; Synthesis of 3H-Labeled Sympathomimetic Amines for Neuronal Mapping; Journal of Labelled Compounds and Radiopharma-ceuticals (1990), 28(7), 831-40.
Kushner, D.J.; Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds; Can. J. Physiol. Pharmacol. 77: 79-88 (1999).
Bauer, L.A.; Influence of Long-term Infusions on Lidocaine Kinetics; Clin. Pharmacol. Ther. 31(4), 433-437 (1982).
Borgstrom, L.; Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect; J Pharm Sci, 77(11) 952-4 (1988).
Browne, T.R.; Chapter 2. Isotope Effect: Implications for pharmaceutical investigations; Stable isotopes in pharmaceutical research; Elsevier; Amsterdam, 1997.
Browne, T.R.; Pharmacokinetic equivalence of stable-isotope-labeled and unlabeled drugs. Phenobarbital in man; J Clin Pharmacol, 22, 309-15 (1982).
Burm, AGL; Pharmacokinetics of Lidocaine and Bupivacaine and stbel isotope labelled analogues: a study in healthy volunteers; Biopharma & Drug Disp, 9 85-95 (1988).
Elison, C; Effect of deuteration of N-CH$—{3}$ Group on Potency and enzymatic N-demethylation of morphine; Science, 134(3485) 1078-9 (1961).
Farmer, P.B.; Synthesis, metabolism, and antitumor activity of deuterated analogues of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; J Med Chem, 21(6) 514-520 (1978).
Fisher, M.B.; The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism; Curr Opin in Drug Disc & Develop 9(1) 101-109 (2006).
Foster, A.B.; Deuterium isotope effects in studies of drug metabolism; Trends in Pharma Sci, 524-527 (1984).
Helfenbein, J.; Isotopic Effect Study of Propofol Deuteration on the Metabolism, Activity, and Toxicity of the Anesthetic; J Med Chem, 45, 5806-5808 (2002).
Lee, H; Deuterium magic angle spinning studies of substrates bound to cytochrome P450; Biochem. 38 10808-13 (1999).
Mamada, K; Pharmacokinetic equivalence of deuterium-labeled and unlabeled phenytoin; Drug Metab Disp. 14(4) 509-11 (1986).
Nelson, S.D.; Primary and B-Secondary Deuterium Isotope Effects in N-Deethylation reactions; J Med Chem. 18(11) 1062-1065 (1975).
Nelson, SD; The use of deuterium isotope effects to probe the active site properties, mechanism, of cytochrome P450-catalyzed reactions, and mechanisms of metabolically dependent toxicity; Drug Metab Disp. 31(12) 1481-98 (2003).
Pohl, L.R..; Determination of Toxic Pathways of Metabolism by Deuterium Substitution; Drug Metab Rev. 15(7) 1335-51 (1984-5).
Rampe, D.; Deuterated analogs of verapamil and nifedipine. Synthesis and biological activity; Eur J Med Chem. 28 259-263 (1993).
Ibrahim, K, et al, Quantitative Measurement of Octopamines and Synephrines in Urine Using Capillary Column Gas Chromatography Negative Ion Chemical Ionization Mass Spectrometry, Anal. Chem, 1984, 56(9), 1695-9.
Phenylephrine-d3 HCI (C9H10NO2D3* HCI), http://synfine.com/products—details.cfm?autoid=620, Catalog name: Synfine Research, catalog # :SI-01296-001, First viewed by applicants' representatives in Sep. 2009.
Crowley, J.R., et al, In-vivo catecholamine formation from phenylephrine, J Pharm Pharmacol., 1983, 35(4), 264-5.
(R)-Phenylephrine-d3 HCI, http://www.trc-canada.com/details.php?CatNumber=P320642, catalog:TRCcatalog No. P320642, downloaded: First viewed by applicants' representatives on Oct. 25, 2009.
[13C,2H3]-Phenylephrine HCI, http://www.alsachim.com/product-C583-glo.bal-Phenylephrine-d3.html, catalog: AlsaChimcatalog No. C583, First viewed by applicants' representatives on Oct. 25, 2009.
R)-(-)-Phenylephrine-d3 HCI, http://www.tlcpharmachem.com/tlc—item.php?upc=P-261&li=le—21&sub=P, Catalog: TLC PharmaChemTLC ID#: P-261, First viewed by applicants' representatives on Oct. 25, 2009.
Phenylephrine-d3 HCI, http://www.cerilliant.com/shoponline/Item—Details.aspx? itemno=8d0cf1d4-5c9d-4fcf-9330-8cac3c377c0d, “catalog: Cerilliantcatalog No. B130341-10”, First viewed by applicants' representatives on Oct. 25, 2009.
Phenylephrine-d3 HCI, http://www.clearsynth.com/view—product—details.asp?product—id=1455, Catalog: Clear Synth LabsCatalog No. CS-01296-001, First viewed by applicants' representatives on Oct. 25, 2009.
(R)-(-) Phenylephrine-d3 HCI, http://www.ejytech.com/P—PROD.htm, Catalog: EJY TechCatalog No. P701-2911, First viewed by applicants' representatives on Oct. 25, 2009.
(R)-(-)-Phenylephrine-d3 HCI, https://www.cdnisotopes.com/us/prodinfo/D-6658.php?ei=nqSagXx/hu0mVnIC/ae6mU5ZW1x8BptHvAx78XfnpSho6OiyXPFhemT5Xu/aOmT5ZW1xw==y, Catalog: C/D/N Isotopes Inc.Catalog No: D-6658, First viewed by applicants' representatives on Oct. 25, 2009.
Material Safety Data Sheet: (R)-(-)-Phenylephrine-d3 HCI, Material Safety Data Sheet: (R)-(-)-Phenylephrine-d3 HCI, Catalog: C/D/N Isotopes Inc.Catalog No: D-6658, MSDS: May 4, 2009.
Gant Thomas G.
Sarshar Sepehr
Auspex Pharmaceuticals, Inc.
Bennett Dennis A.
Davis Brian J
Sertic Michael
LandOfFree
Substituted phenethylamines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted phenethylamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted phenethylamines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4192121